CureDuchenne celebrates Dyne Therapeutics’ public offering on the Nasdaq, under the ticker “DYN”. Today’s initial public offering (IPO) will elevate Dyne’s financial position and accelerate Dyne’s lead programs, which includes Duchenne muscular dystrophy. CureDuchenne values companies like Dyne that utilize fundraising tools such as IPOs to deliver additional dollars to their Duchenne drug discovery process. CureDuchenne’s mission is to find and fund a cure for Duchenne for this generation of boys, and news like Dyne’s provides hope that the Duchenne community will see additional effective treatments soon.
Dyne Therapeutics’ IPO and CureDuchenne’s timely funding is an exemplary model of the CureDuchenne venture philanthropy approach. The CureDuchenne Ventures investment made at a critical time in March 2020 helped Dyne de-risk the science and establish proof-of-concept. They were able to keep working, advance their science and further magnify the value of their pre-clinical work in Duchenne. After today, Dyne will have millions more public dollars available to dedicate to their Duchenne program.
CureDuchenne’s early investment in Dyne was, in part, made possible from donations to CureDuchenne. Dyne’s success today confirms that every donation, big or small, truly can make a difference. If you would like to support groundbreaking treatments for all those living with Duchenne, please consider one of the many ways to support us here: https://www.cureduchenne.org/donate/
You can read more about Dyne’s full therapeutic pipeline here: https://www.dyne-tx.com/pipeline/